GOSS News & Events

Stock futures are higher this morning. Stocks came into the session under heavy pressure after global equities slid to four-month lows, reacting to an 80% surge in oil prices this year and the growing risk of supply disruptions through the Strait of Hormuz.However, oil prices are pulling back, the major averages are jumping, and shares of airlines and cruiselines are up in pre-market trading in the wake of President Trump's message that the U.S. and Iran had "very good and productive conversations" regarding a "complete resolution of hostilities".In pre-market trading, S&P 500 futures rose 1.93%, Nasdaq futures rose 2.04% and Dow futures rose 2.11%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Apogee Therapeuticsup 16% after announcing a 52-week maintenance data from Part A of the Phase 2 APEX clinical trial of zumilokibartFlutter Entertainmentand DraftKingsup 9% and 6%, respectively, after The Wall Street JournalU.S. senators have introduced legislation that will prohibit entities regulated by the Commodity Futures Trading Commission from listing contracts related to sporting eventsSynopsysup 3% after WSJ reports that activist investor Elliot Management has built a multibillion-dollar investment in Synopsys and plans to push the company to make more money from its software and servicesSolo Brandsup 1o% after introducing FY26 guidance ahead of its investor dayDOWN AFTER OIL PRICE DECLINE-Occidentaldown 4%BPdown 3%ConocoPhillipsdown 2%Exxon Mobildown 2%TotalEnergiesdown 1%EOG Resourcesdown 1%Chevrondown 1%Shelldown 1%LOWER -Gossamer Biodown 5% after Cantor Fitzgerald downgraded the stock to Neutral without a price targetN-abledown 5% after William Blair double downgraded shares to Underperform from Outperform without a price target

Reports Q4 revenue $13.799M, consensus $7.52M. "Following our PROSERA topline results, we are focused on fully understanding the PROSERA dataset, engaging with the FDA, and evaluating strategic options and capital allocation to position the Company for the future," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio. "PROSERA narrowly missed the prespecified statistical threshold for its primary endpoint; however, we believe the totality of evidence supports that seralutinib is an active drug in PAH, with the most pronounced effects observed in patients with more advanced disease."